Jane Street Group LLC Trims Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Jane Street Group LLC reduced its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 64.3% in the third quarter, according to its most recent filing with the SEC. The fund owned 27,918 shares of the company’s stock after selling 50,182 shares during the period. Jane Street Group LLC owned approximately 0.05% of ALX Oncology worth $51,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ALXO. Marshall Wace LLP raised its stake in ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after buying an additional 514,133 shares in the last quarter. Point72 Asset Management L.P. bought a new position in ALX Oncology in the second quarter worth approximately $1,834,000. Los Angeles Capital Management LLC bought a new stake in shares of ALX Oncology during the 3rd quarter valued at $469,000. Renaissance Technologies LLC increased its holdings in ALX Oncology by 87.2% in the 2nd quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after acquiring an additional 204,100 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of ALX Oncology in the 2nd quarter worth $1,203,000. 97.97% of the stock is owned by institutional investors.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $1.63 on Thursday. The firm has a 50-day simple moving average of $1.58 and a 200-day simple moving average of $2.57. The stock has a market capitalization of $85.97 million, a price-to-earnings ratio of -0.55 and a beta of 0.98. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. ALX Oncology Holdings Inc. has a 52 week low of $1.19 and a 52 week high of $17.83.

Insider Activity

In related news, Director Rekha Hemrajani bought 30,000 shares of the stock in a transaction on Monday, December 2nd. The stock was bought at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the purchase, the director now directly owns 33,000 shares in the company, valued at $51,150. This represents a 1,000.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 14,443 shares of company stock worth $23,309 over the last three months. Insiders own 33.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and dropped their price target for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a report on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.